AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Market capitalisation stands at Rs 19,771.25 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5 ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...